CVVHDF represents a potential therapy in patients with severe EV-A71-HFMD complicated with cardiopulmonary failure; CVVHDF improved cardiovascular function associated with reduced levels of adrenaline, dopamine, as well as RAAS substances including rennin, angiotensin II, and aldosterone. Here, AGT is linked to hand, foot and mouth disease.